A5008198069- Platelet Disorders and Treatments
- Hemophilia Treatment and Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Blood groups and transfusion
- Blood Coagulation and Thrombosis Mechanisms
- Hemostasis and retained surgical items
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Blood properties and coagulation
- Eosinophilic Disorders and Syndromes
- Blood disorders and treatments
- MicroRNA in disease regulation
- Blood donation and transfusion practices
- Kruppel-like factors research
- Hemoglobinopathies and Related Disorders
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- Blood transfusion and management
- Immunodeficiency and Autoimmune Disorders
- Breast Cancer Treatment Studies
- Orthopaedic implants and arthroplasty
- Antiplatelet Therapy and Cardiovascular Diseases
- Lymphoma Diagnosis and Treatment
Tehran University of Medical Sciences
2016-2025
Imam Khomeini Hospital
2010-2022
Ahvaz Jundishapur University of Medical Sciences
2018
Baqiyatallah University of Medical Sciences
2018
High Institute for Education and Research in Transfusion Medicine
2015-2016
Science Research Laboratory
2016
Tarbiat Modares University
2010
Abstract Glanzmann thrombasthenia (GT) is a rare autosomal recessive disease characterized by prolonged bleeding time with normal platelet count and morphology. It caused the quantitative or qualitative deficiency of glycoprotein IIb–IIIa. In 382 Iranian patients GT diagnosed at single center during period 1969–2001, consanguinity between parents was 86.6%, in accord high frequency intrafamilial marriages Iran. Almost all had abnormal mucocutaneous (epistaxis gum bleeding); follow‐up, 4/5...
Hemarthrosis, particularly in the knee, accounts for most bleeding episodes haemophilia. While joint aspiration has proven effective, role of intra-articular (IA) tranexamic acid (TXA) managing acute hemarthrosis remains unexplored. To assess efficacy and safety knee followed by IA TXA injection haemophilic hemarthrosis. Forty-four adult haemophilia patients with (< 24 h) were randomized to undergo (TXA group) or without (non-TXA (1.5 g/15 mL) injection. Both groups received 75 mL...
This clinical study evaluates the bioequivalence of recombinant factor VIII with Fc fusion protein (rFVIII-Fc) developed by AryoGen Pharmed Company compared to reference product, Elocta® Sobi Co., in severe haemophilia A patients. Fc-fused represents a significant advancement treatment, offering extended half-life and reduced infusion frequency, thus improving patients' adherence treatment quality life. In randomized, double-blind, single-dose crossover trial, 50 Iranian patients were...
Summary Introduction Chronic myeloid leukemia ( CML ) is caused by reciprocal translocation in hematopoietic stem cells HSC s). This forms the BCR ‐ ABL 1 oncogene, which alters several signaling pathways that control malignancy. has three phases: chronic, accelerated, and blast crisis. The micro RNA s (mi or miRs) are noncoding downregulate their target gene targeting 3′ UTR of mRNA through translational inhibition. It been shown mi regulate many biological processes, dysregulation these...
Essentials Congenital afibrinogenemia causes a potentially life-threatening bleeding and clotting tendency. Two human fibrinogen concentrates (HFCs) were compared in randomized pharmacokinetic study. Bioequivalence was not shown for AUCnorm , which significantly larger the new HFC. Increases clot strength comparable, no thromboses or deaths occurred study.Background Human concentrate (HFC) corrects deficiency congenital a-/hypofibrinogenemia. Objectives To assess pharmacokinetics (PK),...
Haemophilic arthropathy (HA) is a debilitating complication of haemophilia which leads to TKA in severe cases.We conducted prospective study the outcome our cohort define outcomes this population and increase cost effectiveness procedure developing country.We reviewed patients with who underwent between April 2010 2014. Patients at least 6 months follow-up were included. Preoperative knee scores (KSS WOMAC) quality life recorded. Radiographic indices registered pre- postoperatively. Any...
Abstract Type 3 von Willebrand disease (VWD3) is a rare and severe bleeding disorder characterized by often undetectable factor (VWF) plasma levels, recessive inheritance pattern, heterogeneous genotype. The objective of this study was to identify the VWF defects in 265 European Iranian patients with VWD3 enrolled 3WINTERS-IPS (Type Von International Registries Inhibitor Prospective Study). All analyses were performed centralized laboratories. genotype studied 231 available DNA (121 [115...
Type 3 von Willebrand disease (VWD) is the most severe form of this owing to almost complete deficiency factor (VWF). Replacement therapy with plasma-derived products containing VWF or recombinant rarely cause development alloantibodies against that may be accompanied by anaphylactic reactions.
BACKGROUND: Iron deficiency is a public problem in women, which contributes to the high percentage of deferred blood donations this group. This study evaluated effect iron supplementation improving stores promote safe donation women. STUDY DESIGN AND METHODS: A total 412 female donors were randomly recruited for study. The volunteers scheduled an initial visit and three subsequent visits at 4‐month intervals possible repeat donation. Each volunteer was given 21 tablets 150 mg ferrous sulfate...
Haemophilic arthropathy of the knee is usually a bilateral affliction. The patients refer for treatment in young ages and do not have major comorbidities, being fit simultaneous total arthroplasty.In this study, we assessed safety cost-effectiveness surgery with haemophilia.Between April 2010 2012, eight (16 knees) underwent 19 (19 unilateral arthroplasty (TKA) at our institution. We compared range motion flexion contracture, KSS, WOMAC score SF36 quality life between two groups. duration...
Introduction: This study compared the efficacy of Aryoseven with Novoseven to control bleeding episodes in patients hemophilia A inhibitors. Methods: Sixty-six were randomized into 2 groups, 4 consecutive block randomization. These groups received and dosages 90 120 μg/kg intravenously every hours. Results: Median (interquartile range) level factor VIII (FVIII) inhibitor B was 15.0 19.0 Bethesda Unit (BU) preadministration. Bleeding onset group 1246 ± 1104 minutes 2301 1693 ( P = .311). The...
In order to establish the efficacy and biosimilar nature of AryoSeven NovoSeven in treatment congenital factor VII (FVII) deficiency, patients received either agent at 30 μg/kg, intravenously per week for 4 weeks, a randomized fashion. The primary aim was compare FVII:coagulation activity (FVII:C), 20 minutes after recombinant activated FVII (rFVIIa) injection, 2 groups. A secondary measure self-reported bleeding. median interquartile baseline range plasma level (FVIIa) groups 1.6 (1.1-14.0)...
Type 3 von Willebrand disease (VWD) is a severe bleeding disorder caused by the virtually complete absence of factor (VWF). Pathophysiological mechanisms VWD like defective synthesis, secretion, and clearance VWF have previously been evaluated using ratios propeptide (VWFpp) over antigen (VWF:Ag) (F)VIII coagulant activity (FVIII:C) VWF:Ag.To investigate whether VWFpp/VWF:Ag FVIII:C/VWF:Ag may also be applied to understand pathophysiological mechanism underlying type VWFpp associated with...
Summary Introduction The JAK 2V617F mutation has emerged in recent years as a diagnostic well treatment target patients with polycythemia vera ( PV ) and essential thrombocythemia ET ). disease phenotype is also influenced by other factors such micro RNA (mi deregulation. aim of this study was to investigate miR‐125 expression level these those obtained from healthy control subjects its correlation 2 allele burden laboratory findings. Methods In total, forty clinical diagnosis were examined...